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Background: The aim of this study is to develop a rat model of bisphosphonates-related osteonecrosis of the jaw
(BRONJ) that would be verified with clinical, radiological and histological examination, and to confirm the influence
of concurrent bisphosphonates and steroids use upon the occurrence and aggravation of BRONJ.
Methods: Twenty seven rats were divided into 3 groups; Saline group (I), Zoledronate group (II), Zoledronate and
Dexamethasone group (III). Rats got weekly intraperitoneal injection for 4 times and extraction of left maxillary and
mandibular 1st, 2nd molars were followed. Consecutive injections were performed, and blood sampling for
measurements of C-terminal crosslinked telopeptide of type I collagen and tartrate-resistant acid phosphate 5b rats
were performed at the time of 2, 4 and 8 weeks. And then, rats were sacrificed and evaluated clinically,
radiologically and histologically.
Results: 12/18 (66.6 %) of experimental group were diagnosed as BRONJ. There was no significant difference in
incidence between zoledronate alone group (ll) and concurrent use of zoledronate and dexamethasone group (lll).
Conclusions: Concurrent use of bisphosphonates and steroids increase incidence of BRONJ compared to saline
group (l). Zoledronate alone group (ll) and concurrent use of zoledronate and dexamethasone group (lll) shows
same incidence of BRONJ. Based on this study, the rat treated with bisphosphonates and steroids can be
considered a novel, reliable and reproducible model to understand pathology of BRONJ.
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Bisphosphonates (BPs) are used to treat and prevent
osteoporosis, bone metastasis of malignant disease,
metabolic bone-disease(e.g. Paget’s disease, osteogenesis
imperfecta, primary hyperparathyroidism) which causes
secondary hypercalcemia, pathologic fracture [1–3].
BPs contain 2 phosphonates, same structure as pyro-
phosphate, and suppress the activity of osteoclasts, conse-
quently decrease loss of bone volume [4, 5]. BPs are
classified into 2 categories - Nitrogen containing BPs
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provided the original work is properly creditedand Non-nitrogen containing BP(clodronate, etidronate,
etc.). Nitrogen containing BPs are hardly metabolized, and
depress osteoclasts strongly, while Non-nitrogen contain-
ing BPs are metabolized quickly [6, 7].
In 2003, Marx first reported osteonecrosis of the jaw
of patients, medicated by nitrogen containing BPs
(pamidronate(Aredia®), zoledronate (Zometa®)) [8]. This
report has triggered many discussions for pathogenesis,
incidence, and treatment of BRONJ.
The American Society for Bone and Mineral
Research(ASBMR) Task Force defines bisphosphonates-
related osteonecrosis of jaw, as an area of exposed bone
in the maxillofacial region that did not heal within
8 weeks in a patient who had been exposed to BPs, not
to radiation therapy [9].
The incidence of BRONJ has not been defined, according
to the research of ASBMR, BRONJ associated with oralle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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1:100,000 to 1:10,000. However, it could be higher, depend-
ing on duration of therapy, and BRONJ associated with
intravenous administration of high dose of BPs for cancer
therapy is estimated 1:100 to 1:10 [9–12].
There are many risk factors for BRONJ – kind of BPs,
administration route, patient age, pre-existing periodon-
tal disease, invasive dental treatment, concurrent use of
drugs [13, 14].
Kyrgidis reported that invasive dental treatment
including tooth extraction is one of the significant
factors for BRONJ [13]. Recently, ASBMR Task Force
considers that systemic risk factors associated with
cancer therapy, affect occurrence and aggravation of
BRONJ, and concurrent use of chemo-regimen and
steroids has synergic effects on BRONJ [14, 15].
Most of BRONJ patients were diagnosed with multiple
myeloma, breast cancer, and prostate cancer. Furthermore,
they were all injected with Nitrogen-containing BPs and
steroids, such as dexamethasone intravenously. However, it
has not been defined, interaction between systemic risk
factors, concurrent medications, and occurrence and aggra-
vation of BRONJ. Thus, the authors aimed to develop a rat
model of BRONJ, and to confirm how concurrent use of
BPs and steroids can affect occurrence and aggravation of
BRONJ in this study.
Methods
Twenty seven female Spraque-Dawley rats (250–300 g)
were used and 54 sites (left maxilla and mandible). We
followed the rules of Institutional Animal Care and Use
Committee (IACUC), department of laboratory animal
medicine, medical research center, Yonsei University,
college of medicine.
All rats(n = 27) are divided into 3 groups (Table 1). Saline
group (l) was injected with normal saline intra-peritoneally.
Zoledronate group (II) was injected with zoledronic acid
0.2 mg/kg intra-peritoneally. Zoledronate and dexametha-
sone group (lll) was injected with zoledronic acid 0.2 mg/
kg, and dexamethasone 5 mg/kg intra-peritoneally, at the
same time. Total study period takes 12 weeks (Fig. 1.).
All rats were adapted for 1 week, according to the
rules of Institutional Animal Care and Use Committee
(IACUC). From the first day of study, for 4 weeks,
medications are injected intravenously every 1 weekable 1 We used 27 rats, divided into 3 groups
roup
umber
Group information Medication
(n = 9) Control Normal saline
(n = 9) Zoledronic acid injection Zoledronic acid 0.2 mg/kg
(n = 9) Zoledronic acid +
Dexamet hasone injection
Zoledronic acid 0.2 mg/kg +
Dexamethasone 5 mg/kgT
G
n
1
2
3by same experimentor. 3 days after 4th injection, left
1st, 2nd molars of maxilla and mandible were
extracted. All extraction were done aseptically, under
general anesthesia (Tiletamine/zolazepam®-milan, Italy,
xylazine-Rompun® Bayer AG, Leverkusen, Germany).
We used dental explorer, in procedure of peritomy, sublux-
ation, luxation, extraction, and curettage, sequentially.
After extraction, we injected meloxicam(Metacam®,
Boehringer-Ingelheim, Germany), 10 mg/kg intra-
peritoneally to control post-operative pain, according
to IACUC.
2, 4, 8 weeks after extraction, every 3 rats of saline
group (l) and 2,2,5 rats of each zoledronate group (ll)
and zoledronate and dexamethasone group (lll) were
sacrificed in CO2 asphyxiation chamber, taking blood
samples infraorbitally at the same time. Blood samples
are used on ELISA kit, to analyze CTX, TRACP 5b level.
All the specimens were evaluated by clinical, radiological,
histological examination.
Clinical examination
All the specimens were reviewed to confirm incomplete
oral mucosal coverage on necrotic alveolar bone and
sequestra formation, then photographed, and preserved
with 10 % buffered-formalin immediately.
Radiological examination
All the specimens were radiographed by Plain X-ray
with standard dental radiographic film.
(Voltage(kV) = 60, Current(mA) = 70, Exposure(s) =
0.08)
Histological examination
All the specimens were decalcified with 10 % ethylenedi-
aminetetraacetic acid (EDTA) for 1 week, and embedded
to paraffin. After embedding to paraffin, maxilla and
mandible were resected 4 μm thickness, anterio-
posteriorly.
We used Hematoxylin & Eosin staining to see
inflammatory cells, necrotic alveolar bone, and empty
lacunae of osteoclasts. Also, we confirmed BRONJ
with histologic features, calculating incidence of ONJ
in experimental group.
Laboratory & statistical examination
1 ~ 1.5 cc whole blood was taken from infra-orbitally,
right before extraction of teeth and sacrifice, 2, 4,
8 weeks after extraction. Whole blood was centrifuged
and applied to ELISA kit to evaluate CTX(C-terminal
crosslinked telopeptide of type I collagen), TRACP
5b(Serum tartrate-resistant acid phosphate) level. CTX,
Non-helical C-terminal of Type I bone tropocollagen, is
a biomarker that evaluate the degree of type I collagen
resorption and activity of osteoclasts [16]. We used
Fig. 1 Time table of study is shown above. It takes 12 weeks, and 2,4,8 weeks after extraction, we sacrifice every 3 rats of control group, 2,2,5 rats
of experimental group. We take blood samples at the same time
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and laboratory finding. Serum tartrate-resistant acid
phosphate 5b (TRACP 5b) is a novel marker for moni-
toring anti-resorptive therapy in patients using BPs
[17, 18]. Herein, the authors used TRACP 5b as well
as CTX, as the evidence for occurrence of BRONJ.
Bivariate analysis (Independant t-test)
We did independant t-test (Mann–Whitney test), be-
cause of small number of animal groups to find TRACP
5b can distinguish between normal and BRONJ group
with statistical significance.
Linear mixed test
Linear mixed test shows group & time effects for
TRACP 5b regarding BRONJ risk prediction.
Results
Clinical examination
In experimental group(group 2, 3), 12/18 rats(66.6 %)
showed osteonecrosis of jaw.
Seven of 10 rats, that were sacrificed 8 weeks after
extraction, showed osteonecrosis of jaw, relatively high
incidence of BRONJ(70 %). It explains that injection
period can be a risk factor for BRONJ (Fig. 2).Fig. 2 Incidence of ONJ lesion(%), experimental groupWe compared clinical appearances of maxillary &
mandibular ridge in rats. Control group shows complete
healing of oral mucosa (Fig. 3a). Zoledronate injection
group(Z group) and Zoledronate & Dexamethasone
injection group(Z+D group) show incomplete healing of
oral mucosa, similar incidence but, different in size of
exposed, necrotic alveolar bone (Fig. 3b and c).
Radiological examination
Control group shows complete healing of jaw bone -
linear opaque radio-density around extraction socket
(Fig. 4a). Experimental group shows incomplete healing
of jaw bone - mottled trabecular pattern around extrac-
tion socket, more definite in Z+D group (Fig. 4b and c).
Histological examination
All specimens in control group show complete healing of
extraction sockets. Experimental group shows incomplete
healing of extraction site. There were inflammatory cells
surrounding necrotic alveolar bone with empty lacunae
(Fig. 5a), and sequestra apart from alveolar bone (Fig. 5b).
Ulcerative overlying mucosa invaginates into extraction
socket (Fig. 5c).
Laboratory & statistical examination
Here is the laboratory result (Fig. 6). TRACP 5b shows
more reliable value to indicate BRONJ than CTX level
- TRACP 5b consistently shows lower value of BRONJ
group than normal healing group.
Bivariate analysis (Independant t-test)
We did independant t-test (Mann–Whitney test) because
of small number of animal groups.
In this test, TRACP 5b can distinguish normal and
BRONJ group with statistical significance(P value
<0.05) (Table 2). TRACP 5b has lower diurnal variabil-
ity than CTX, although time and TRACP 5b level are
not inversely proportional.
Fig. 3 Representative photographs of gross clinical appearance of maxillary & mandibular ridge in rats(All sacrificed 8 weeks after extraction). a
Control group shows complete healing of oral mucosa covering extraction site. b Z group shows incomplete healing of oral mucosa, showing
exposed, necrotic, alveolar bone. c Z+D group shows incomplete healing of oral mucosa, showing definitely wide, exposed necrotic
alveolar bone
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Linear mixed test shows group & time effects for
TRACP 5b regarding BRONJ risk prediction. Here is the
equation considering ‘Effect factor’ (eSE) (Table 3).
It concludes that
1. TRACP 5b has e0.18 effect to distinguish BRONJ &
Non-BRONJ group, with statistical significance. (P
value = 0.001)
2. TRACP 5b has e0.02 effect to predict incidence of
BRONJ with time change, without statistical
significance. (P value = 0.023)
3. It is possible to use TRACP 5b to diagnose BRONJ
to a certain degree.Fig. 4 Representative radiograph of extraction sites on maxillary & mandib
opaque radio-density around extraction socket (control group). b Mottled t
wider mottled trabecular pattern around extraction socket (Z+D group)Discussion
There are many studies to investigate interaction
between bisphosphonates and other drugs – steroids
[15, 19], vitamin D [20], on incidence of BRONJ.
The concurrent use of bisphosphonates and steroids
has definite clinical relevance with BRONJ, as many
BRONJ patients being treated for multiple myeloma,
breast cancer receive both drugs [13]. The purpose of
this study focused on development of rat model of
BRONJ to confirm how concurrent use of BPs and ste-
roids can affect occurrence and aggravation of BRONJ.
We used equivalent dose of zoledronate and dexa-
methasone. For example, multiple myeloma patients take
zoledronic acid intravenously, 1.6 × 10 −4 g/kg/week. Weular ridge in rats(All sacrificed 8 weeks after extraction). a Linear
rabecular pattern around extraction socket (Z group). c More definite,
Fig. 5 Representative histologic features of extraction sites(All sacrificed 8 weeks after extraction). a Inflammatory cells(neutrophils) surround
necrotic alveolar bone with empty lacunae (Z group, Mn, ×200, sacrificed 8 weeks after extraction). b Sequestra formation apart from alveolar
bone with empty lacunae (Z group, Mn, ×100, sacrificed 8 weeks after extraction). c Ulcerative overlying mucosa invaginates into extraction
socket, and necrotic bone with empty lacunae on the surface of exposed alveolar bone (Z+D group, Mx, ×50, sacrificed 8 weeks after extraction)
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that effective dose of zoledronic acid, injected peritoneally
can be lower than that of intravenous injection. It resulted
in increased concentration and frequency of bisphospho-
nates injection, more than usual clinical use for cancer
patients. As a result, we have 66.6 % of BRONJ rats, much
higher than human incidence of BRONJ, 1–10 %.
In control group, we observed that new bone formation
starts 2 days after extraction, new bone fills extraction
socket completely 2 weeks after extraction, as previous
studies report [21, 22].
In our animal model, it appeared that bisphosphonates
alone and concurrent use of bisphosphonates and steroids
has similar incidence of BRONJ in clinical, radiological,
histological examination.
It can be explained in two ways.
First, root remnants may affect healing mechanism of
BRONJ. We used dental explorer extracting molar
teeth, in process of subluxation, luxation, extraction,
curettage. Complete extraction and curettage makes
bigger bone defect than incomplete extraction. Rat
molar has more divergent roots than those of human,
resulting in more chances to leave root remnants.Fig. 6 CTX shows no tendancy neither between normal and BRONJ group
BRONJ group than normal healing group, although time and TRACP 5b levBadros reported that patients with pamidronate and
dentoalveolar surgery together have 7 times higher
incidence of BRONJ than those who have pamidronate
alone [23]. That explains bigger bone defect increases
incidence of BRONJ.
Second, BRONJ patients are usually older and take many
kinds of drugs than rats. Mean life of Spraque-Dawley rat
is 24 months, 96 weeks. We used 8 week-rats, it takes
12 weeks to finish this study. So they are 20 weeks-old
and still adolescent. Zoledronate alone or concurrent use
of zoledronate and steroid may make no difference to
immune system of adolescent rats.
Steroids may reduce post-operative inflammation to
help healing, but in our study, cumulative doses of
steroids can modify the bony and mucosal reponse to
delay healing, causing avascular necrosis [24], increasing
BRONJ risk [19, 25, 26], as previous studies report.
There are many biomarkers to diagnose BRONJ – CTX
[16], NTX level, TRACP 5b [17], RANKL/OPG ratio, etc.
[27].
We chose CTX and TRACP 5b to confirm the diagno-
sis of BRONJ. TRACP 5b has two isotypes- Type 5a &
Type 5b. Most of TRACP 5b are type 5b, they exist in, nor within each group. TRACP 5b consistently shows lower value of
el are not inversely proportional
Table 2 TRACP 5b can distinguish between normal and BRONJ
group with statistical significance
CTX Non-BRONJ (6/18) BRONJ (12/18) P value
Mean(pg/mL) Mean(pg/mL)
Baseline 150.63 ± 50.69 171.36 ± 45.05 0.23
2 weeks 126.24 ± 21.97 122.79 ± 24.58 0.87
4 weeks 175.13 ± 48.28 172.71 ± 40.78 0.90
8 weeks 91.69 ± 53.30 127.53 ± 38.00 0.12
TRACP 5b Non-BRONJ (6/18) BRONJ (12/18) P value
Mean(U/L) Mean(U/L)
Baseline 1.49 ± 0.19 1.30 ± 0.07 0.00
2 weeks 1.44 ± 0.18 1.33 ± 0.05 0.01
4 weeks 1.42 ± 0.17 1.34 ± 0.04 0.07
8 weeks 1.53 ± 0.16 1.37 ± 0.12 0.03
(P value < 0.05)
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osteoclasts, analyzing TRACP 5b quantitatively. Besides,
TRACP 5b is not affected by liver and kidney function,
it has little diurnal variability than CTX.
There were many reports using bone turn-over
markers including TRACP 5b [28], but not in field of
BRONJ, that represents much to this study.
In this model, TRACP 5b shows more reliable value to
indicate BRONJ than CTX level - TRACP 5b consistently
shows lower value of BRONJ group than normal healing
group, although time and TRACP 5b level are not
inversely proportional. There are many bone turn-over
markers including TRACP 5b, but clinical use is not
established yet. There should be more research for clinical
use of TRACP 5b, predicting possibility of BRONJ
incidence, staging and managing of BRONJ patients.
Conclusion
We established successful animal model for BRONJ, and
obtained following results.
1) Concurrent use of bisphosphonates and steroids
increase incidence of BRONJ.
2) It has little chance of spontaneous BRONJ, resulting
from concurrent use of bisphosphonates andTable 3 Linear mixed test equation and effect factor
Estimated measures (ES) 95 % CI P value
BRONJ 0.18 ± 0.05 0.08 ± 0.28 0.001
Time 0.02 ± 0.01 0.003 ± 0.05 0.023
BRONJ × Time −0.02 ± 0.02 −0.05 ± 0.01 0.229
Effect factor = eSE
y = Xβ + Zu + ε
y: TRACP 5b measures
β : Fixed effects
u: Random effects
ε: Random errorsteroids only, surgical stimulus, such as extraction
plays important role as trigger factor, increasing
incidence of BRONJ.
3) Based on this study, the rat treated with
bisphosphonates and steroids can be considered a
novel, reliable and reproducible model to understand
better pathology of BRONJ.
4) TRACP 5b can be a reliable biomarker to confirm
BRONJ.
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